Pullikotil Philomena, Vincent Martin, Nichol Stuart T, Seidah Nabil G
Laboratories of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec H2W 1R7, Canada.
J Biol Chem. 2004 Apr 23;279(17):17338-47. doi: 10.1074/jbc.M313764200. Epub 2004 Feb 16.
Processing of membrane-bound transcription factors such as sterol regulatory element-binding proteins (SREBPs) and the ER-stress response factor ATF6, and glycoproteins of some hemorrhagic fever viruses are initiated by the proprotein convertase SKI-1/S1P. So far, no cellular protein-based inhibitor of the hydrophobic-amino acid specific SKI-1 is known. The prosegment of the basic-amino acid specific convertases (e.g. furin and PC5) or alpha(1)-PDX, a variant of alpha(1)-antitrypsin (alpha(1)-AT) exhibiting an RIPR(358) sequence at the reactive site loop, were shown to potently inhibit these secretory proteinases. Accordingly, we tested the SKI-1-inhibitory potential of various point mutants of either the 198 amino acid preprosegment of SKI-1-(1-198) or alpha(1)-AT. Transient transfections data showed that, out of numerous mutants studied, the R134E prosegment mutant or the alpha(1)-AT reactive site loop variants RRVL(358), RRYL(358) and RRIL(358) are the best specific cellular inhibitors of SKI-1. The observed inhibition of the processing of endogenous SREBP-2, exogenous ATF6 and a PDGF-A (RRLL(86)) variant were >55% and reach approximately 80% in stable transfectants. We also show that SKI-1 forms SDS-stable complexes with these alpha(1)-AT variants, but not with wild-type alpha(1)-AT or alpha(1)-PDX. Finally, these inhibitors were also shown to affect the processing and stability of the Crimean-Congo hemorrhagic fever virus glycoprotein.
膜结合转录因子(如固醇调节元件结合蛋白(SREBPs))和内质网应激反应因子ATF6以及某些出血热病毒的糖蛋白的加工过程是由前体蛋白转化酶SKI-1/S1P启动的。到目前为止,尚未发现基于细胞蛋白的疏水氨基酸特异性SKI-1抑制剂。碱性氨基酸特异性转化酶(如弗林蛋白酶和PC5)的前肽段或α1-抗胰蛋白酶(α1-AT)的变体α1-PDX,其反应位点环处具有RIPR(358)序列,已显示出能有效抑制这些分泌蛋白酶。因此,我们测试了SKI-1-(1-198)的198个氨基酸前肽段或α1-AT的各种点突变体对SKI-1的抑制潜力。瞬时转染数据表明,在所研究的众多突变体中,R134E前肽段突变体或α1-AT反应位点环变体RRVL(358)、RRYL(358)和RRIL(358)是SKI-1最好的特异性细胞抑制剂。观察到的对内源性SREBP-2、外源性ATF6和血小板衍生生长因子-A(RRLL(86))变体加工的抑制率>55%,在稳定转染细胞中可达约80%。我们还表明,SKI-1与这些α1-AT变体形成SDS稳定复合物,但不与野生型α1-AT或α1-PDX形成复合物。最后,这些抑制剂还显示出会影响克里米亚-刚果出血热病毒糖蛋白的加工和稳定性。